GLRA3 encodes the alpha-3 subunit of glycine receptors, which function as ligand-gated chloride channels that regulate neuronal excitability 1. The gene produces two alternatively spliced variants (alpha3L and alpha3K) that differ in desensitization kinetics, with the cytoplasmic loop between transmembrane domains 3 and 4 serving as a critical determinant of channel inactivation 1. GLRA3 is widely expressed throughout the human central nervous system and contributes to inhibitory neurotransmission 1. Disease associations include diabetic complications, where genome-wide association studies have identified GLRA3 variants as significantly associated with diabetic albuminuria in Finnish type 1 diabetes patients, particularly in those with poor glycemic control 23. Additionally, GLRA3 variants show genome-wide significant association with chr4 postsurgical pain, potentially through prostaglandin E2-mediated pain processing pathways 4. A case report describes autism in a patient with a chr4 deletion including GLRA3, suggesting potential neurodevelopmental roles 5. However, population studies found no association between GLRA3 variants and idiopathic generalized epilepsies 6. The clinical significance lies in its potential as a therapeutic target for pain management and diabetic complications, though further validation across populations is needed.